Don't Jump to Saxenda for Weight Loss in Adolescents
May 2021
Saxenda (liraglutide) will be a new option to help tackle obesity in adolescents 12 and up...not just in adults.
About 30% of Canadian kids aged 5 to 17 are overweight or obese. This may lead to adulthood obesity and a higher risk of chronic problems...type 2 diabetes, heart disease, sleep apnea, etc.
Explain that 1 year of the GLP-1 agonist Saxenda in adolescents leads to about a 5% decrease in BMI or body weight compared to placebo...or about 5 kg for a 100 kg patient.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive